Recent Press Releases

European Medicines Agency recommends approval of two new treatment options for rare cancers

European Medicines Agency recommends approval of two new treatment options for rare cancers Imbruvica and Zydelig to be used in different forms of blood cancers The European Medicines Agency's...

AbbVie Reports Second-Quarter 2014 Financial Results

- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 (Reports GAAP EPS of $0.68) - Delivers Second-Quarter Revenue of $4.926 Billion, an Increase of 5.0...

HIKMA AGREES TO ACQUIRE BEN VENUE MANUFACTURING SITE ADDING R&D CAPABILITIES AND CAPACITY

HIKMA AGREES TO ACQUIRE BEN VENUE MANUFACTURING SITE ADDING R&D CAPABILITIES AND CAPACITY London, 24 July 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:...

Bristol-Myers Squibb Company (BMY) Appoints Jitendra Tyagi As India Country Head

Bristol-Myers Squibb Company (BMY) Appoints Jitendra Tyagi As India Country Head Bristol-Myers Squibb (BMS) India appointed Jitendra Tyagi as the BMS India country head. He has successfully performed...

Amgen Announces Webcast of 2014 Second Quarter Financial Results

THOUSAND OAKS, Calif., July 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report

Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0%

DUBLIN, July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has rec

Lilly Reports Second-Quarter 2014 Results

INDIANAPOLIS, July 24, 2014 /PRNewswire/ --

GSK CEO and CFO Interviewed on Q2 2014 Results and Strategy Update

LONDON, July 23, 2014 /PRNewswire/ --

U.S. Food And Drug Administration Approves Gilead's Zydelig® (idelalisib) For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma

U.S. Food And Drug Administration Approves Gilead's Zydelig® (idelalisib) For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma -- 82 Percent Reduction...

FDA accepts Sandoz application for biosimilar filgrastim

FDA accepts Sandoz application for biosimilar filgrastim Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price...

Roche with good half year performance

Roche with good half year performance Group sales up 5% at constant exchange rates1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs Cancer medicine...

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia ‐- Novel Antidote Enables Quicker Response to Inherited Life‐Threatening Condition ‐‐ ‐‐ Orphan Drug...

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety...

Lilly Reports Second-Quarter 2014 Results

Lilly Reports Second-Quarter 2014 Results INDIANAPOLIS, July 24, 2014 /PRNewswire/ -- Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S. patent expirations for Cymbalta and...

Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight

Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight The European Medicines Agency has concluded its review of emergency contraceptives...

BIOGEN IDEC SECOND QUARTER 2014 REVENUES INCREASE 40% TO $2.4 BILLION; COMPANY RAISES FINANCIAL GUIDANCE FOR THE YEAR

Growth Bolstered by Increased Adoption of TECFIDERA® in New Markets Worldwide Quarter Highlights include Approval of ELOCTATETM for Hemophilia A; Positive Phase 3 Read Out for Multiple...

Biotie: Selincro enters the market in Spain

TURKU, Finland, Jul 22, 2014 (GLOBE NEWSWIRE via COMTEX) -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Spain. According to the terms...

Johnson & Johnson Announces $5 Billion Share Repurchase Program

NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson JNJ +1.09% today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's...

Majority of Biotech/Pharma Employees Poised to Job Hunt

Employees in this sector indicate high interest in near-future job changes ATLANTA, July 15, 2014 /PRNewswire/ -- Employees in the U.S. biotech and pharma industries express significant interest in...